重组人改构白介素11的聚乙二醇修饰工艺优化研究
|
摘要
目的:提高聚乙二醇(PEG)修饰重组人改构白介素11(interleukin 11 mutein,mIL-11)反应中的单位点修饰率。方法:在考察pH、蛋白浓度、PEG与蛋白的配比等单因素对单位点修饰率影响的基础上,采用DoE设计对修饰工艺参数进行优化并建立响应最大化预测模型。结果:在pH 8. 2,mIL-11浓度0. 8 mg·mL~(-1),mPEG-SC:mIL-11(摩尔比) 5. 5,修饰温度2～8℃,修饰时间1 h的条件下,单位点修饰率最大可达到53%。结论:经3批验证实验,结果与模型预测值相符,方法可行。
Objective: To improve the mono-modification rate for PEGylation of recombinant human interleukin-11 mutein (mIL-11). Methods: The effects of pH,concentration of mIL-11 and molar ratio of m PEGSC/mIL-11 on the yield of mono-PEGylated mIL-11 were investigated. Based on this,the optimization of technological parameters for PEGylation was carried out by Design of Experiment (DoE) and maximum response model was established. Results: The optimized reaction condition for the highest yield of mono-PEGylated mIL-11 was as follows:pH of 8. 2,mIL-11 concentration of 0. 8 mg·mL~(-1),molar ratio of m PEG-SC/mIL-11 5. 5,and reaction time of 1 h at 2 ～ 8 ℃. Under the optimized reaction condition,a high mono-modification rate of 53% was achieved. Conclusion:The model-predicted yield was consistent with the validation experiment result by 3 batches validation.
Objective: To improve the mono-modification rate for PEGylation of recombinant human interleukin-11 mutein (mIL-11). Methods: The effects of pH,concentration of mIL-11 and molar ratio of m PEGSC/mIL-11 on the yield of mono-PEGylated mIL-11 were investigated. Based on this,the optimization of technological parameters for PEGylation was carried out by Design of Experiment (DoE) and maximum response model was established. Results: The optimized reaction condition for the highest yield of mono-PEGylated mIL-11 was as follows:pH of 8. 2,mIL-11 concentration of 0. 8 mg·mL~(-1),molar ratio of m PEG-SC/mIL-11 5. 5,and reaction time of 1 h at 2 ～ 8 ℃. Under the optimized reaction condition,a high mono-modification rate of 53% was achieved. Conclusion:The model-predicted yield was consistent with the validation experiment result by 3 batches validation.
引文
[1]马杉姗,马素永,丁大有,等.治疗血小板减少症的新药研究进展[J].中国药学杂志,2012,47(21):1690-1693.
[2]马杉姗,汤晓闯,李开通,等.聚乙二醇化重组人改构白细胞介素11在食蟹猴体内药代动力学检测方法的建立[J].国际药学研究杂志,2016,43(2):351-354.
[3]惠希武,陈虹,黄秉仁.蛋白质、多肽类药物聚乙二醇修饰的研究进展[J].中国生物制品学杂志,2012,25(4):520-524.
[4]TAKAGI A,YAMASHITA N,YOSHIOKA T,et al.Enhanced pharmacological activity of recombinant human interleukin-11(rhIL11)by chemical modification with polyethylene glycol[J].J Control Release,2007,119(3):271-278.
[5]李智华,胡满仓,阎玲梅,等.人白细胞介素11的定点聚乙二醇修饰[J].中国生物工程杂志,2009,29(6):20-24.
[6]PASUT G.Pegylation of biological molecules and potential benefits:pharmaco-logical properties of certolizumab pegol[J].Bio Drugs,2014,28(Suppl 1):S15-S23.
[7]边蕾,石屹峰.蛋白质药物长效化技术的现状和进展[J].中国生物工程杂志,2009,29(2):114-118.
[8]RYAN SM,MANTOVANI G,WANG X,et al.Advances in PE-Gylation of important biotechmolecules:delivery aspects[J].Expert Opin Drug Del,2008,5(4):371-383.
[9]PASUT G,VERONESE FM.Polymerdrug conjugation,recent achievements and general strategies[J].Prog Polym Sci,2007,32(8-9):933-961.
[10]SWIERCZEWSKA M,LEE KC,LEE S.What is the future of PEGylated therapies?[J].Expert Opin Emerg Dr,2015,20(4):531-536.
[11]PIGEON JG.Statistics for experimenters:design,innovation,and discovery[J].Technometrics,2006,60(48):303-304.
[12]JUNG Y,AHN H,KIM DS,et al.Improvement of biological and pharmacokinetic features of human interleukin-11 by site-directed mutagenesis[J].Biochem Bioph Res Co,2011,405(1):399-404.
[13]WU S,ZHANG Y,XU L,et al.Multicenter,randomized study of genetically modified recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in cancer patients receiving chemotherapy[J].Support Care Cancer,2012,20(8):1875-1884.
[14]姜忠义,许松伟,王艳强.蛋白质和肽类分子的聚乙二醇化化学[J].有机化学,2003,23(12):1340-1347.
[15]VERONESE FM.Peptide and protein PEGylation:a review of problems and solutions[J].Biomaterials,2001,22(5):405-417.
[16]姜忠义,高蓉,许松伟,等.蛋白质的化学修饰研究进展[J].现代化工,2001,21(8):25-28.
[2]马杉姗,汤晓闯,李开通,等.聚乙二醇化重组人改构白细胞介素11在食蟹猴体内药代动力学检测方法的建立[J].国际药学研究杂志,2016,43(2):351-354.
[3]惠希武,陈虹,黄秉仁.蛋白质、多肽类药物聚乙二醇修饰的研究进展[J].中国生物制品学杂志,2012,25(4):520-524.
[4]TAKAGI A,YAMASHITA N,YOSHIOKA T,et al.Enhanced pharmacological activity of recombinant human interleukin-11(rhIL11)by chemical modification with polyethylene glycol[J].J Control Release,2007,119(3):271-278.
[5]李智华,胡满仓,阎玲梅,等.人白细胞介素11的定点聚乙二醇修饰[J].中国生物工程杂志,2009,29(6):20-24.
[6]PASUT G.Pegylation of biological molecules and potential benefits:pharmaco-logical properties of certolizumab pegol[J].Bio Drugs,2014,28(Suppl 1):S15-S23.
[7]边蕾,石屹峰.蛋白质药物长效化技术的现状和进展[J].中国生物工程杂志,2009,29(2):114-118.
[8]RYAN SM,MANTOVANI G,WANG X,et al.Advances in PE-Gylation of important biotechmolecules:delivery aspects[J].Expert Opin Drug Del,2008,5(4):371-383.
[9]PASUT G,VERONESE FM.Polymerdrug conjugation,recent achievements and general strategies[J].Prog Polym Sci,2007,32(8-9):933-961.
[10]SWIERCZEWSKA M,LEE KC,LEE S.What is the future of PEGylated therapies?[J].Expert Opin Emerg Dr,2015,20(4):531-536.
[11]PIGEON JG.Statistics for experimenters:design,innovation,and discovery[J].Technometrics,2006,60(48):303-304.
[12]JUNG Y,AHN H,KIM DS,et al.Improvement of biological and pharmacokinetic features of human interleukin-11 by site-directed mutagenesis[J].Biochem Bioph Res Co,2011,405(1):399-404.
[13]WU S,ZHANG Y,XU L,et al.Multicenter,randomized study of genetically modified recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in cancer patients receiving chemotherapy[J].Support Care Cancer,2012,20(8):1875-1884.
[14]姜忠义,许松伟,王艳强.蛋白质和肽类分子的聚乙二醇化化学[J].有机化学,2003,23(12):1340-1347.
[15]VERONESE FM.Peptide and protein PEGylation:a review of problems and solutions[J].Biomaterials,2001,22(5):405-417.
[16]姜忠义,高蓉,许松伟,等.蛋白质的化学修饰研究进展[J].现代化工,2001,21(8):25-28.